# Doxorubicin Liposome

## Lipo-Dox inj 20mg (自費用)

| TAH Drug Code      | [ILIPD](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ILIPD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Used for the treatment of AIDS-related Kaposi's sarcoma in patients with CD4 count <200 CD4 lymphocytes/mm3 and lesions on mucosa， skin， or internal organs. Used for the treatment of progressive or metastatic ovarian cancer in patients who have failed first-line platinum-based chemotherapy or have experienced recurrence. Can be used as a single therapy for metastatic breast cancer patients with a consideration of cardiac disease risk. Can be used in combination with bortezomib to treat progressive multiple myeloma patients who have received at least one prior treatment and have either undergone or are unsuitable for bone marrow transplantation.                                                                                                                                                                                                                      |
| Dosing             | [Breast cancer/Ovarian cancer] 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.[Multiple myeloma] 30 mg/m2 on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 mg/m2 on days 1， 4， 8， and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment. Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. Doses of bortezomib should be at least 72 hours apart. [AIDS-related Kaposi sarcoma (AIDS-KS)] 20 mg/m2 once every 2-3 weeks for 2-3 months is recommended to achieve a therapeutic response. Continue treatment as needed to maintain a therapeutic response. Avoid intervals shorter than 10 days. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Severe hypersensitivity (including anaphylaxis) to doxorubicin liposomal， conventional doxorubicin， or any component of the formulation. Breast-feeding. AIDS-KS patients effectively treat with local or systemic α-interferon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Infusion-associated acute reactions， stomatitis， Palmar-plantar erythrodysesthesia， cardiac toxicity. Nausea， leukopenia， neutropenia， anemia & thrombocytopenia. Asthenia， alopecia， fever， diarrhea. Resp infections， laboratory abnormalities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/doxorubicin-liposome-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## Lipo-Dox inj 20mg (健保用)

| TAH Drug Code      | [ILIPD1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ILIPD1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Used for the treatment of AIDS-related Kaposi's sarcoma in patients with CD4 count <200 CD4 lymphocytes/mm3 and lesions on mucosa， skin， or internal organs. Used for the treatment of progressive or metastatic ovarian cancer in patients who have failed first-line platinum-based chemotherapy or have experienced recurrence. Can be used as a single therapy for metastatic breast cancer patients with a consideration of cardiac disease risk. Can be used in combination with bortezomib to treat progressive multiple myeloma patients who have received at least one prior treatment and have either undergone or are unsuitable for bone marrow transplantation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | [Breast cancer/Ovarian cancer] 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment. [Multiple myeloma] 30 mg/m2 on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 mg/m2 on days 1， 4， 8， and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment. Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. Doses of bortezomib should be at least 72 hours apart. [AIDS-related Kaposi sarcoma (AIDS-KS)] 20 mg/m2 once every 2-3 weeks for 2-3 months is recommended to achieve a therapeutic response. Continue treatment as needed to maintain a therapeutic response. Avoid intervals shorter than 10 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Severe hypersensitivity (including anaphylaxis) to doxorubicin liposomal， conventional doxorubicin， or any component of the formulation. Breast-feeding. AIDS-KS patients effectively treat with local or systemic α-interferon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Infusion-associated acute reactions， stomatitis， Palmar-plantar erythrodysesthesia， cardiac toxicity. Nausea， leukopenia， neutropenia， anemia & thrombocytopenia. Asthenia， alopecia， fever， diarrhea. Resp infections， laboratory abnormalities. Dermatologic: Alopecia， Hand-foot syndrome due to cytotoxic therapy (ovarian cancer， 50.6% AIDS-related Kaposi's sarcoma， 3.4% multiple myeloma， 19% )， Rash (ovarian cancer， 28.5%AIDS-related Kaposi's sarcoma， 1% to 5% multiple myeloma， 22% ) Gastrointestinal: Constipation (multiple myeloma， 31% )， Diarrhea (ovarian cancer， 20.9%AIDS-related Kaposi's sarcoma， 7.8%multiple myeloma， 46% )， Loss of appetite (ovarian cancer， 20.1% AIDS-related Kaposi's sarcoma， 1% to 5%multiple myeloma， 19% )， Nausea (ovarian cancer， 46% AIDS-related Kaposi's sarcoma， 16.9%multiple myeloma， 48% )， Stomatitis (ovarian cancer， 41.4% AIDS-related Kaposi's sarcoma， 6.8%multiple myeloma， 20% )， Vomiting (ovarian cancer， 32.6%AIDS-related Kaposi's sarcoma， 7.8%multiple myeloma， 32%) Hematologic: Decreased platelet count (ovarian cancer， 13% to 24.2%; AIDS-related Kaposi's sarcoma， 60.9%; multiple myeloma， 33%)， Hemoglobin low (ovarian cancer， 40.2% to 52.6%; AIDS-related Kaposi's sarcoma， 55.4%; multiple myeloma， 25% )， Neutrophil count abnormal (ovarian cancer， 19% to 35.1%; AIDS-related Kaposi's sarcoma， 48.9%; multiple myeloma， 36%) Neurologic: Asthenia (ovarian cancer， 40.2% AIDS-related Kaposi's sarcoma， 9.9% multiple myeloma， 22% ) Psychiatric: Fatigue (multiple myeloma， 36%; ) Other: Drug fever (ovarian cancer， 21.3%AIDS-related Kaposi's sarcoma， 9.1%multiple myeloma， 31% ) |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| More Info          | [UpToDate](https://www.uptodate.com/contents/doxorubicin-liposome-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

